Sanity Medical Vayamed

Vayamed and telemedicine pioneer Telaleaf launch exclusive partnership

Berlin, February 8, 2022 – German medical cannabis specialist Vayamed and the telemedicine platform Telaleaf agreed on an exclusive partnership to strengthen telemedicine in cannabis therapy in Germany. The focus will be on therapy quality, patient centered pricing, individual therapy plans, and equitable therapy access. Telaleaf is a pioneer in cannabis-based telemedicine from Canada established in 2020 and will now launch its services in the German healthcare system.

Telaleaf, a telemedicine company transforming the access and delivery of medical cannabis care to patients, and Berlin-based medical cannabis brand Vayamed are pleased to announce a strategic partnership to strengthening the quality of telemedicine services in cannabis therapy in Germany through premium quality virtual care and to improve access, in line with Vayamed’s brand vision: “Medicine from Nature. Customized for Patients”. Vayamed and Telaleaf are driven by the vision that telemedicine will continue to move healthcare delivery from clinic to home, and will become the standard in cannabis-based medicine. Doctor visits to consult about Vayamed products and treatment options are planned as well as further programs in the field of talent support and further training at leading medical faculties nationwide. 

“The importance of telemedicine in the German healthcare system will continue to grow. It offers many benefits for doctors, patients and the healthcare system, for example better access and treatment quality, qualified trainings, and improved health insurance reimbursement levels through special training offers for doctors. Together with Telaleaf, we want to improve therapies with medical cannabis in Germany through the utilization of telemedicine”, said Thimo V. Schmitt-Lord, Director New Markets & Innovation at Vayamed.

“In order to fully realize the vision of cannabis-based medicine as the advanced, alternative medicinal modality it has proven to be, Telaleaf has entirely reimagined the cannabis healthcare delivery model such that all necessary medical services, tools and resources come together for patients and doctors under one unified field. Our joint mission with Vayamed is to drive better health outcomes for patients with personalized virtual care that is sustained by expert-led medicinal cannabis training and education,” said Telaleaf CEO Gavin Treanor.

Telaleaf collaborates with leading experts such as Prof. Kirsten Müller-Vahl, M.D., and Franjo Grothenhermen, M.D., and the medical cannabis training for participating doctors is provided at the highest educational level in cooperation with Dresden International University.


About Vayamed 
Medical cannabis specialist Vayamed, a brand of Berlin-based health and life science company Sanity Group, specializes in the development and distribution of innovative cannabinoid-based medicinal products for the European market and, as a reliable provider, is committed to making medical cannabis accessible to doctors, pharmacists and patients. 

About Telaleaf
Telaleaf is a telemedicine company transforming the delivery of cannabis care by connecting patients to expert doctors, trained in cannabis-based medicine, who conduct virtual medical visits and provide personalized treatment plans. Our aim is to improve patient outcomes, by improving the patient experience with high quality treatment, ease of access and expert-led training to doctors, for the most advanced virtual care in cannabis medicine.

Endosane Sanity Medical

Endosane and UCI investigate the efficacy of new compounds for the treatment of PTSD

Berlin/Irvine, January 18, 2022 – Endosane Pharmaceuticals, a Berlin-based pharmaceutical company specialising in the systematic exploration and use of the endocannabinoid system for the treatment of neurological, neuropsychiatric, and psychiatric disorders, and the University of California Irvine (UCI) have agreed to investigate the efficacy of two innovative compounds for the treatment of post-traumatic stress disorder through a series of preclinical studies. The studies will be conducted in the laboratory of the internationally renowned neuropharmacologist and leading endocannabinoid system researcher, Professor Daniele Piomelli, who played a crucial role in developing the drug class to be investigated. Due to the specific mode of action of the compounds, a significantly more effective treatment of PTSD with fewer side effects could be possible. Results are expected as early as the first half of 2022. 

Endosane Pharmaceuticals is taking an essential step towards realising its vision for the future: In addition to the already advanced development of the cannabinoid-based compound for the treatment of schizophrenia, Endosane is vigorously investigating further compounds in its own portfolio for the treatment of other mental disorders. Unlike the potential schizophrenia drug, the development of these compounds are still in the so-called preclinical phase, but existing data on related molecules strongly indicate the potential clinical efficacy. If successful, the imminent studies will constitute a solid basis for rapid further development. Endosane is aiming to start clinical trials within 2022.

Post-traumatic stress disorders are a group of mental disorders that are widespread and all characterised by the experience of significant trauma. Those affected are permanently restricted in their way of life. There are often considerable impairments of sleep and the re-experiencing of traumatic life situations. According to the current research, PTSD is caused by an overload of the brain’s processing capacities for dealing with the negative memories created by the trauma, which can resurface in an uncontrolled manner. Currently, available medications are primarily aimed at helping people cope with the symptoms they are experiencing, particularly anxiety, panic attacks, and sleep disorders. 

Support for processing the trauma
Like all the other active pharmaceuticals in Endosane’s portfolio, the molecules in question act via the body’s own endocannabinoid system. However, unlike other active ingredients, these are not cannabinoids but synthetic molecules that alter the concentration of the body’s own endocannabinoids by inhibiting certain enzymes. The development of these molecules was based on various basic research studies in memory research, which showed a connection between changes in the balance of the body’s endocannabinoid system and the ability to process memories. The results suggest that it is possible to influence the processing of trauma by targeting this system. Therefore, the new compounds would not primarily treat the visible symptoms of PTSD, such as anxiety, panic attacks and insomnia, but the root cause, which is the processing of negative memories. 

“We see the endocannabinoid system, as with our active substance for the treatment of schizophrenia, as a modulator of the neurophysiological balance that is offering the possibility of addressing not only the visible symptoms, but the cause itself,” says Prof. Dr. Leweke, Medical Director of Endosane Pharmaceuticals. Even more importantly, the use of the endocannabinoid system would intervene much more ‘gently’ in the neurophysiological structure of the patient than currently available drugs. The chance of considerably reduced side effects is therefore significant. 

Collaboration with UCI
It is no coincidence that the upcoming studies are being carried out at UCI. Prof. Dr. Daniele Piomelli is responsible for research in this field. Like Prof. Leweke, Prof. Piomelli is a pioneer in the field of study into the endocannabinoid system. In particular, the drug class being researched – so-called FAAH-inhibitors – was co-developed by him. “We are very pleased to be able to explore these compounds together with Prof. Piomelli at UCI,” said Max Narr, Managing Director of Endosane Pharmaceuticals. “We are very optimistic that the preclinical studies will provide a clear indication regarding efficacy. If this assumption is confirmed, we will aim to conduct a Phase I clinical trial within the next year.” 

About Endosane Pharmaceuticals

Endosane Pharmaceuticals GmbH is a pharmaceutical company based in Berlin aiming to develop and commercialise new finished drugs to treat neurological, neuropsychiatric, and psychiatric conditions. Therefore, Endosane is systematically exploring the endocannabinoid system for its potential to modulate neurophysiological balance. The current compound portfolio contains compounds for treating several indications, including schizophrenia, social anxiety disorder, and post-traumatic stress disorder. More information at
About Prof. Dr. Daniele Piomelli
Prof. Dr. Piomelli is a Professor of Anatomy and Neurobiology at the School of Medicine. He holds the Louise Turner Arnold Chair in Neurosciences and joint appointments at the Biological Chemistry and Pharmacology departments. He is also a director at the Institute for the Study of Cannabis and Editor-in-Chief of “Cannabis and Cannabinoid Research”.

Sanity Group

Sanity Group appreciates the controlled dispensing of cannabis as stated in the coalition agreement

Berlin, November 24, 2021 – In their coalition agreement presented today, the parties SPD, Bündnis 90/Die Grünen and FDP have spoken out favouring controlled dispensing of cannabis. They would like to legalise the sale of cannabis for consumption purposes. “We are introducing the controlled dispensing of cannabis to adults for enjoyment in licensed stores,” reads the coalition agreement of the coalition. Berlin-based cannabis company Sanity Group appreciated the decision.


“We are delighted that SPD, Bündnis 90/Die Grünen and FDP have agreed on the legalisation of cannabis for recreational use via controlled distribution to adults. We have been advocating a more liberal and responsible approach to cannabis for many years and firmly believe that a controlled dispensing is the right way forward. In this way, not only can the black market be curbed and product quality ensured, but youth and consumer protection can also be guaranteed through expert education and advice. The parties of the new German government have now laid the foundation, but the details still need to be worked out: Clear legislation and regulation are needed to define, among other things, the conditions for cultivation, processing, logistics and licensed distribution, thus ensuring quality and supply security. Here, we can also learn from the experience of other countries, such as Canada or the USA. Youth protection and prevention are also elementary and indispensable. We are clearly in favour of the revenue from a potential cannabis tax flowing into youth protection as well as target group-specific educational measures,” says Finn Hänsel, founder of the Sanity Group, who can very well imagine setting up and operating a system of licensed specialist stores. At the same time, the 39-year-old would like the planned legalisation to also uniformly regulate the handling of CBD products in Germany: “Here, we have had an unclear legal situation for all parties involved for years – this topic should now also be addressed in a future law.”

Fabian Friede, who founded Sanity Group together with Hänsel in 2018 and is also CEO of the pharmaceutical subsidiary Vayamed, adds: “The supply of patients with medical cannabis must not be restricted or jeopardised by a future controlled dispensing to adults for consumption purposes. We advocate that the medical cannabis market be clearly separated from the recreational cannabis market, which can be achieved through licensed stores.” In addition, Friede would like to see a simplified prescription of medical cannabis: “The authorisation requirement of health insurance companies must be abolished to make it easier for patients to access therapy with medical cannabis.”

About Sanity Group

The Berlin-based Sanity Group aims to improve people’s quality of life through the sensible use of cannabinoids and the utilisation of the endocannabinoid system. In addition to pharmaceuticals, the focus is also on wellbeing and cosmetic products based on cannabinoids. In parallel, Sanity Group is also working and researching new medical products, innovative dosage forms, and technological products and services to further develop the infrastructure. Sanity Group was founded in 2018 by Finn Age Hänsel and Fabian Friede and now employs a team of over 120 people. Sanity Group includes Vayamed (medical cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), Belfry Medical (medical products), Sanatio CBD, VAAY (CBD products) and This Place (functional natural cosmetics), among others. For more information, visit:

Sanity Group

Sanity Group Closes $3.5M Follow-On Investment by Casa Verde Capital

November 3, 2021, Berlin – Berlin-based cannabis start-up Sanity Group announced today it has closed a $3.5M follow-on investment from Casa Verde Capital, representing a second closing of the company’s $45M Series A financing round. This brings total funds raised by Sanity Group to $76.5M to date, the highest level of funding attained by any European cannabis start-up. It is also Casa Verde’s first investment into Germany, the largest and most profitable medical cannabis market in Europe.

“We are proud to welcome Casa Verde as our latest shareholder and we are delighted to have the backing of the cannabis industry’s pre-eminent venture firm. Casa Verde’s commitment to Sanity Group and to Germany further confirms we are on the right strategic path. It is also evidence of growing momentum in the European market as more countries move to initiate pilot projects to legalize and improve access to medical cannabis programs,” says Finn Hänsel, founder and managing director of Sanity Group.

Fabian Friede, who co-founded the company with Hänsel in 2018, adds: “We are excited to benefit from Casa Verde’s vast expertise and experience in the US cannabis market. Yoni Meyer and Karan Wadhera have been a crucial part of our journey since the announcement of our seed round two years ago. We are now pleased to officially expand our collaboration with them through Casa Verde’s direct stake in our business.”

Sanity Group will use the additional investment to advance medical cannabis research and expand its own business, including the development and distribution of medical cannabis and finished medicinal products, as well as its consumer health division through its VAAY and This Place brands.

“We have watched Sanity Group’s growth trajectory closely for the last two years. The Company’s leadership, track record and vision clearly set it on the right path to becoming a leading European cannabis brand,” says Yoni Meyer, Partner at Casa Verde.

Casa Verde joins Sanity Group’s notable investor community, including Swiss VC Redalpine, German HV Capital, Calyx, SevenVentures, Bitburger Ventures, and prominent business angels such as Black Eyed Peas frontman, Hollywood actress Alyssa Milano, music producer Scooter Braun and German soccer player Mario Götze.


About Sanity Group
Sanity Group aims to improve people’s quality of life through the sensible use of cannabinoids and the utilization of the endocannabinoid system. In addition to pharmaceuticals, the focus is also on wellbeing and cosmetic products based on cannabinoids. Sanity Group was founded in 2018 by Finn Age Hänsel and Fabian Friede and now employs a team of over 120 people.

About Casa Verde 
Casa Verde is the leading venture capital firm focusing on the cannabis industry. As both the domestic and international cannabis markets continue to evolve and mature, Casa Verde maintains a view that the cannabis industry will be among the most compelling investment themes of our generation.

Sanity Group

Endosane: International scientists team up with Sanity Group in a joint-venture aiming to develop a new generation of “game changing” psychiatric drugs with significantly reduced side effect profile​

Berlin, October 5th, 2021 – Sanity Group, a health and life-science company focused on natural compounds and cannabinoids, and an international team of scientists are now jointly developing pharmaceuticals for the treatment of neuropsychiatric and psychiatric disorders such as schizophrenia or anxiety disorders. This collaboration is based on the systematic research and targeting of the body’s endocannabinoid system. The newly founded company, Endosane Pharmaceuticals GmbH (, will build on decades worth of research by the scientists involved while resuming advanced clinical trials (Phase II) with a potential schizophrenia drug.

By founding Endosane Pharmaceuticals GmbH, Sanity Group successfully implements another of its visions: Fueled by the successful financing round in summer of 2021, the Berlin-based company is joining one of the world’s leading research and development projects for finished pharmaceuticals specifically targeting the endocannabinoid system for therapeutic use. Endosane’s development pipeline already contains several psychiatric drugs for the treatment of neuropsychiatric and psychiatric disorders, in particular schizophrenia and anxiety disorders. Developments around schizophrenia are the most advanced. With Phase II studies already completed and two ongoing, approval is forecasted for as early as 2025. 

Decades of research by a renowned team of scientific experts

The scientific basis for Endosane is laid in years of research by an international team led by the renowned German neurologist and psychiatrist Prof. Dr. F. Markus Leweke (University of Sydney). Prior to his current engagement, Prof. Leweke led the Center of Excellence for Psychiatry and Psychotherapy Research at the Central Institute of Mental Health in Mannheim at the Ruprecht-Karls University in Heidelberg, where he and his research group are still scientifically active today. As early as the mid-1990s, Prof. Leweke started to engage in the systematic research of the endocannabinoid system and its role and therapeutic  potential in psychiatric disorders.

In collaboration with Dr. Cathrin Rohleder, a neurobiologist and long-time colleague, he collected data indicating a clear connection between various psychiatric disorders and the endocannabinoid system. Based hereon, the possibility of drug treatment for selected indications – especially schizophrenia- began. While most conventional psychiatric drugs primarily target the “visible” symptoms of psychiatric disorders, this treatment aims to readjust the endocannabinoid system disturbed in many symptomatic patients.. “Figuratively speaking, we are treating these disorders, i.e. schizophrenia in particular, much closer to the cause than current drugs,” says Prof. Dr. Leweke. Even more important, according to Prof. Leweke, is that such use of the endocannabinoid system would be a much “gentler” intervention in the molecular neurobiology of patients than currently available drugs. “If the clinical data collected so far is confirmed in the further course of phases II and III, we would be in a position to offer a drug with a significantly improved side effect profile,” said Dr. Rohleder, who is coordinating the clinical development. “This would be a huge step in quality of life for affected individuals.” 

Endosane is a key building block in realizing Sanity Group vision

Sanity Group’s approach to systematically exploit the potential of the endocannabinoid system always included the development of finished drugs. Therefore, the set-up of Endosane fits perfectly into Sanity Group’s vision to improve people’s quality of life through the use of cannabis and the utilization of the endocannabinoid system. Sanity Group already develops and distributes medical cannabis in various pharmaceutical forms; in addition, the company offers over-the-counter cannabinoid-based consumer goods such as CBD oils and cosmetics. “Our goal is to explore and harness the full potential of the endocannabinoid system. We are glad to have found partners in Prof. Dr. Leweke, Dr. Rohleder and their team with whom we can realize our long-term vision also with regard to the development of finished drugs in the field of psychiatric drugs,” said Finn Hänsel and Fabian Friede, founders and managing directors of Sanity Group.

Combination of scientific excellence with the agility and mindset of a start-up company

In addition to the scientific management of the company, which is comprised of Prof. Dr. Leweke as Chief Medical Officer and Dr. Rohleder as Chief Scientific Officer, Max Narr completes the Endosane management team as Managing Director coming from Sanity Group. Narr is a fully qualified lawyer from the pharmaceutical and biotech practice of an international law firm. He subsequently assumed management roles in a public German medium-sized chemical company,  where he was responsible for strategy and M&A.  Before joining Sanity Group, he was in charge of restructuring a company delivering into the pharmaceutical supply chain and integrating it into a larger group. Narr joined Sanity Group in October 2020 and has been responsible for the new business and strategy. In this role, he finished the development of the concept of Endosane together with Prof. Leweke and Dr. Rohleder. “Dr. Rohleder, Prof. Leweke and I quickly realized that our prior experiences and skill sets complement each other very well. With Endosane, we have a huge opportunity to not only be commercially very successful, but to directly help people who are currently suffering the burden of serious adverse effects of their medication,” said Narr. To be able to meet the immense challenge of pharmaceutical development, Endosane will, in the future, draw on the infrastructure and expertise of Sanity Group. In addition, Endosane’s management is supported by an experienced advisory board, which includes members from academia as well as seasoned industry leaders. 


About the Sanity Group

Sanity Group has set itself the goal of improving the quality of life of people through the sensible use of cannabinoids and the use of the endocannabinoid system. In addition to pharmaceuticals, it also focuses on wellbeing and cosmetic products based on cannabinoids. In parallel, Sanity Group is working and researching new medical products, innovative dosage forms as well as  technological products and services to further develop the infrastructure. Sanity Group was founded in 2018 by Finn Age Hänsel and Fabian Friede and now employs a team of over 100 people at its headquarters in Berlin-Mitte and its research site near Frankfurt am Main. Sanity Group brands include Vayamed (pharmaceuticals), VAAY (CBD products) and This Place (functional cosmetics). More information at

About Prof. Dr. F. Markus Leweke

Prof. Dr. Leweke is Professor at the University of Sydney and Chair in Youth Depression Studies at the Brain and Mind Centre. For many years he was Head of the Center of Excellence for Psychiatry and Psychotherapy Research, Central Institute of Mental Health Mannheim at the Ruprecht-Karls-University Heidelberg. As a practicing psychiatrist and psychotherapist, Prof. Dr. Leweke has over 25 years of experience in the treatment of psychiatric disorders. In the mid-1990s, he was one of the first to engage in research on the endocannabinoid system and its role and therapeutic potential in psychiatric disorders. He is an Associate Editor of the scientific journal Cannabis and Cannabinoid Research.

Sanity Group

Liqui-Patch: Sanity Group and epinamics launch strategic partnership for transdermal cannabinoid applications

Berlin, September 22, 2021 – Berlin-based health and life science company Sanity Group and Berlin-based tech company epinamics are launching a strategic innovation partnership: Sanity Group will receive exclusive usage and marketing rights for epinamics’ patented Liqui-Patch® technology for all cannabinoid market segments and markets in the EU, UK and Switzerland.

Liqui-Patch® is an innovative, film-forming spray solution for the transdermal application of active ingredients. A team of researchers around epinamics founder Prof. Dr. Wolfgang Kehr developed the technology over several years and spun it off as a management spin-off from Bayer-Schering. Based on the Liqui-Patch® technology, the Sanity Group will break new ground in the transdermal delivery of cannabinoids. Products are planned in the medical field as well as in the wellbeing and sports sector.

“With Liqui-Patch® transdermal technology, we are pushing open the door to the cannabis market of the future: smart, innovative products with high therapeutic benefits make medical cannabis a strong option for entirely new patient groups,” says Thimo V. Schmitt-Lord, Director Market Development & Sector Innovation at Vayamed, the pharmaceutical subsidiary of Sanity Group. “Liqui-Patch® also represents Vayamed’s brand vision in a special way: medicine from nature, tailored for patient well-being.”

Active ingredient patch for spraying

Compared to conventional dermal or transdermal applications, Liqui-Patch®, which is sprayed onto the skin as a transparent film with a pump spray, offers far-reaching advantages: The spray is transparent, dries quickly on the skin and does not smear; skin irritation, such as that caused by the adhesive strips of conventional solid patches, can be avoided by the technology. In addition to high bioavailability, it also provides a constant release of active ingredients over many hours. Furthermore, it offers a safe alternative to the use of gels containing active ingredients, where there is always a risk of active ingredient transfer. Last but not least, the Liqui-Patch® enables more efficient use of active ingredients for almost all disease areas compared to conventional methods.

“Anyone who has ever worn an active ingredient patch for several days knows the problem: the skin is irritated and painful. Active ingredient patches, which transport drugs through the skin into the bloodstream, have become established. However, they have some disadvantages, often leading to restricted freedom of movement and painful skin reactions. We were looking for an alternative to this and were able to develop it in the form of the Liqui-Patch®,” says epinamics Managing Director Prof. Dr. Kehr.

For more information on the Liqui-Patch, visit


About the Sanity Group

The Sanity Group has set itself the goal of improving people’s quality of life through the sensible use of cannabis in Europe. In addition to pharmaceuticals, the focus is also on consumer health products based on cannabinoids. In parallel, Sanity Group is also working and researching new medical products, innovative dosage forms, and technological products and services to further develop the infrastructure. Sanity Group was founded in 2018 by Finn Age Hänsel and Fabian Friede and now employs a team of over 100 people at its headquarters in Berlin-Mitte and its research site near Frankfurt am Main. Sanity Group brands include Vayamed (pharmaceuticals), VAAY (CBD products) and This Place (functional cosmetics). The company is supported strategically and financially by Redalpine, HV Capital, Calyx, Navy Capital, Bitburger Ventures, SevenVentures and various business angels such as Casa Verde founder Karan Wadhera, music producer, TV presenter Klaas Heufer-Umlauf, professional soccer player Mario Götze and model Stefanie Giesinger. More information at

About epinamics

Berlin-based epinamics GmbH is a specialised and globally oriented development company in the field of advanced drug delivery. The owner-managed company focuses on the Liqui-Patch®, a patent-protected platform technology for dermal and transdermal delivery of active ingredients. The Liqui-Patch® can be conveniently and safely applied to the skin and forms an invisible film within 90 seconds from which the respective active ingredient is released. The procedure replaces the currently prevailing patch technology (i.e. plastic stick-on patches), as it is lighter, gentler on the skin and completely inconspicuous to apply.